Leukemia

Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?

Chase Doyle

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Leukemia, Value-Based Care

San Diego, CA—For children and young adults diagnosed with acute lymphoblastic leukemia (ALL), receiving treatment at specialized cancer centers has been associated with improved outcomes versus nonspecialized centers, but this comes at an increased cost, according to data presented at ASH 2018. [ Read More ]

Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia

Chase Doyle

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Emerging Therapies, Leukemia

San Diego, CA—A chimeric antigen receptor (CAR) T-cell therapy that targets CD19 and CD22 molecules has demonstrated safety and efficacy, in patients with relapsed or refractory B-cell precursor acute lymphoblastic lymphoma (ALL), with response rates consistent with CAR T-cell therapies that target CD19 alone. [ Read More ]

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia

Wayne Kuznar

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Leukemia

San Diego, CA—Front-line ibrutinib (Imbruvica) therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine (Ben­deka) and rituximab (Rituxan) in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018. [ Read More ]

First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation

Charles Bankhead

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Leukemia

San Diego, CA—More than 40% of older patients with acute myeloid leukemia (AML) associated with an IDH2 mutation achieved complete remission when treated with the IDH2 inhibitor enasidenib (Idhifa), according to results of a mutation-driven clinical trial substudy presented at ASH 2018. [ Read More ]

Researchers Identify First Mutation to Explain Resistance to Venetoclax

Phoebe Starr

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Leukemia

San Diego, CA—The BCL2 Gly101Val mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia (CLL). The BCL2 Gly101Val mutation is unique to CLL and so far has not been described in other cancers. [ Read More ]

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL

Phoebe Starr

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - Leukemia

San Diego, CA—A 2-year duration of combination immunotherapy with ven­etoclax (Venclexta) and rituximab (Ri­tuxan) improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine (Ben­deka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017. [ Read More ]

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum - Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease that is characterized by uncontrolled proliferation of undifferentiated myeloid progenitors. While these leukemic blasts accumulate in the bone marrow and peripheral blood, impairment of normal hematopoiesis may lead to a reduction in the number of differentiated myeloid cells (granulocytes, neutrophils, monocytes, erythrocytes, megakaryocytes). Associated symptoms and consequences include anemia, bleeding, and an increased risk for infection. [ Read More ]